Truscreen Group Ltd
NZX:TRU
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Truscreen Group Ltd
NZX:TRU
|
NZ |
|
AGL Energy Ltd
ASX:AGL
|
AU |
|
AP Holdings Co Ltd
TSE:3175
|
JP |
|
Comany Inc
TSE:7945
|
JP |
|
Vista Energy SAB de CV
F:1CIA
|
MX |
|
IDT Corp
NYSE:IDT
|
US |
|
Acesian Partners Ltd
SGX:5FW
|
SG |
|
C
|
Coinbase Global Inc
XETRA:1QZ
|
US |
|
Paranovus Entertainment Technology Ltd
NASDAQ:PAVS
|
CN |
|
M
|
Mr Price Group Ltd
JSE:MRP
|
ZA |
|
Kinatico Ltd
ASX:KYP
|
AU |
|
Mondi PLC
LSE:MNDI
|
UK |
|
Unifin Financiera SAB de CV
BMV:UNIFINA
|
MX |
Truscreen Group Ltd
TruScreen Group Ltd. engages in the development, manufacture, and sale of cancer detection device and systems. The firm is engaged in the business of the development, manufacturing and sale of cancer detection devices and systems. Its cervical cancer screening device offers technology in cervical screening, providing detection of precancerous and cancerous cervical cells to help improve the health and well-being of women worldwide. Its real-time cervical cancer technology utilizes a digital wand, which is placed on the surface of the cervix to measure electrical and optical signals from the surrounding tissues. A sophisticated algorithm framework is utilized to detect pre-cancerous change, or cervical intraepithelial neoplasia (CIN), by optical and electrical measurement of cervical tissue. The product offers an approach to cervical screening, resolving ongoing issues with Pap smear (Pap tests), including failed samples, patient follow-up, patient discomfort and the need for supporting laboratory infrastructure.
TruScreen Group Ltd. engages in the development, manufacture, and sale of cancer detection device and systems. The firm is engaged in the business of the development, manufacturing and sale of cancer detection devices and systems. Its cervical cancer screening device offers technology in cervical screening, providing detection of precancerous and cancerous cervical cells to help improve the health and well-being of women worldwide. Its real-time cervical cancer technology utilizes a digital wand, which is placed on the surface of the cervix to measure electrical and optical signals from the surrounding tissues. A sophisticated algorithm framework is utilized to detect pre-cancerous change, or cervical intraepithelial neoplasia (CIN), by optical and electrical measurement of cervical tissue. The product offers an approach to cervical screening, resolving ongoing issues with Pap smear (Pap tests), including failed samples, patient follow-up, patient discomfort and the need for supporting laboratory infrastructure.
